Na Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Na Yan has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ke Cheng
Department of Biomedical Engineering, Columbia University, New York, USA
6 shared publications - Dashuai Zhu
Department of Biomedical Engineering, Columbia University, New York, NY, USA
4 shared publications - Mengrui Liu
Department of Biomedical Engineering, Columbia University, New York, NY, USA
4 shared publications Savannah Weihang Zhang
3 shared publicationsShiqi Hu
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
3 shared publications- Shiqi Hu
Department of Biomedical Engineering, Columbia University, New York, NY, USA
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 63, 942-952
Inhalable bioadhesive barrier for lung protection and clearance of fine particulate matter
Fine particulate matter (PM) can bypass nasal filtration and accumulate in the lower respiratory tract, where prolonged deposition may cause chronic inflammation, pulmonary fibrosis, and other respiratory diseases. Although commercial nasal sprays offer protection in the upper airways, they are inadequate for safeguarding the lower respiratory tract and lung. In this study, we introduce an inhalable bioadhesive barrier (IBB) specifically engineered to deposit in the lower airways, where it forms an adhesive hydrogel barrier upon contact with airway mucus and actively scavenges inhaled fine PM. With optimized aerodynamic properties, IBB can efficiently deposit throughout the bronchi and bronchioles, providing protection for up to 8 h. The IBB captures and encapsulates inhaled PM, enabling its clearance from the airways within 48 h, thus preventing long-term retention. Compared to commercial nasal sprays, intranasal inhalation of IBB markedly improved protection against chronic silica exposure in a murine silicosis model. Large animal studies further demonstrated uniform and extensive airway coverage by IBB in porcine models, suggesting strong translational potential for human respiratory protection. This approach provides a safe, efficient, and cost-effective strategy for preventing respiratory diseases induced by chronic exposure to respirable fine particulates.
- 1 September 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 63, 942-952
Open AccessInhalable bioadhesive barrier for lung protection and clearance of fine particulate matter
Fine particulate matter (PM) can bypass nasal filtration and accumulate in the lower respiratory tract, where prolonged deposition may cause chronic inflammation, pulmonary fibrosis, and other respiratory diseases. Although commercial nasal sprays offer protection in the upper airways, they are inadequate for safeguarding the lower respiratory tract and lung. In this study, we introduce an inhalable bioadhesive barrier (IBB) specifically engineered to deposit in the lower airways, where it forms an adhesive hydrogel barrier upon contact with airway mucus and actively scavenges inhaled fine PM. With optimized aerodynamic properties, IBB can efficiently deposit throughout the bronchi and bronchioles, providing protection for up to 8 h. The IBB captures and encapsulates inhaled PM, enabling its clearance from the airways within 48 h, thus preventing long-term retention. Compared to commercial nasal sprays, intranasal inhalation of IBB markedly improved protection against chronic silica exposure in a murine silicosis model. Large animal studies further demonstrated uniform and extensive airway coverage by IBB in porcine models, suggesting strong translational potential for human respiratory protection. This approach provides a safe, efficient, and cost-effective strategy for preventing respiratory diseases induced by chronic exposure to respirable fine particulates.
- Open Access
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation
Metastasis accounts for 90% of cancer-related deaths. Extravasation is a necessary step for cancer metastasis. Currently, there are no drugs that specially target extravasation. Most cancer therapies target either proliferation or angiogenesis. We previously identified “angiopellosis” as the dominant mechanism by which vascular endothelial cells undergo conformational changes and actively “push” circulating cancer cells out of blood vessels. In this study, we developed an image-based high-throughput drug screening assay by coculturing cancer membrane–coated spheres with endothelial monolayers. Through this platform, we identified Bay 61-3606 as a lead angiopellosis inhibitor. Bay 61-3606 substantially reduced cancer cluster extravasation, an activity solely supported by angiopellosis and associated with higher metastatic potential, in both zebrafish and mouse models. Furthermore, Bay 61-3606 decreased distant metastases in murine models of lung carcinoma and triple-negative breast cancer. Mechanistically, Bay 61-3606 targeted the c-Jun amino-terminal kinase signaling pathway, down-regulating COL8A1 expression in endothelial cells and impairing the angiopellosis process.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Open AccessScreening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation
Metastasis accounts for 90% of cancer-related deaths. Extravasation is a necessary step for cancer metastasis. Currently, there are no drugs that specially target extravasation. Most cancer therapies target either proliferation or angiogenesis. We previously identified “angiopellosis” as the dominant mechanism by which vascular endothelial cells undergo conformational changes and actively “push” circulating cancer cells out of blood vessels. In this study, we developed an image-based high-throughput drug screening assay by coculturing cancer membrane–coated spheres with endothelial monolayers. Through this platform, we identified Bay 61-3606 as a lead angiopellosis inhibitor. Bay 61-3606 substantially reduced cancer cluster extravasation, an activity solely supported by angiopellosis and associated with higher metastatic potential, in both zebrafish and mouse models. Furthermore, Bay 61-3606 decreased distant metastases in murine models of lung carcinoma and triple-negative breast cancer. Mechanistically, Bay 61-3606 targeted the c-Jun amino-terminal kinase signaling pathway, down-regulating COL8A1 expression in endothelial cells and impairing the angiopellosis process.
- Open Access
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaed2483
Active protein-capturing hydrogel for broad-spectrum pathogen defense
Proteinaceous agents, including viral particles and allergenic proteins, play central roles in infection, inflammation, and immune dysregulation, yet few materials can broadly neutralize them through direct protein capture. Here, we present an inhalable protein trap (IPT), an active hydrogel that rapidly immobilizes diverse amine-containing biomolecules via NHS-amine chemistry. Structural optimization enables IPT to stably incorporate a high density of reactive NHS esters that remain functional under physiological conditions, allowing efficient protein capture at mucosal surfaces. Upon hydration, powdery IPT rapidly forms an active barrier that covalently traps proteins and proteinaceous particles within minutes. This nonselective capture mechanism allows IPT to bind viral particles, allergens released from pollen or fungi, and soluble immune mediators such as histamine. Across multiple animal models, including allergic rhinitis, pollen-induced allergy, and viral infection, IPT consistently outperformed commercial barrier sprays in blocking pathogenic proteins and mitigating disease progression. These results establish IPT as a versatile platform for broad-spectrum protection at biological interfaces.
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaed2483
Open AccessActive protein-capturing hydrogel for broad-spectrum pathogen defense
Proteinaceous agents, including viral particles and allergenic proteins, play central roles in infection, inflammation, and immune dysregulation, yet few materials can broadly neutralize them through direct protein capture. Here, we present an inhalable protein trap (IPT), an active hydrogel that rapidly immobilizes diverse amine-containing biomolecules via NHS-amine chemistry. Structural optimization enables IPT to stably incorporate a high density of reactive NHS esters that remain functional under physiological conditions, allowing efficient protein capture at mucosal surfaces. Upon hydration, powdery IPT rapidly forms an active barrier that covalently traps proteins and proteinaceous particles within minutes. This nonselective capture mechanism allows IPT to bind viral particles, allergens released from pollen or fungi, and soluble immune mediators such as histamine. Across multiple animal models, including allergic rhinitis, pollen-induced allergy, and viral infection, IPT consistently outperformed commercial barrier sprays in blocking pathogenic proteins and mitigating disease progression. These results establish IPT as a versatile platform for broad-spectrum protection at biological interfaces.
- Top Cited PapersOpen Access
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , edau9394
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Self-amplifying RNA (saRNA) enables sustained protein expression from a single administration. In this study, we developed an intramuscular saRNA-lipid nanoparticle (saNppa-LNP) therapy encoding natriuretic peptide type A ( Nppa ) for cardioprotection. A single injection induced sustained pro–atrial natriuretic peptide (pro-ANP) secretion for 4 weeks; pro-ANP was subsequently cleaved by the cardiac protease corin into active ANP, producing robust cardioprotection in mouse and swine myocardial infarction models. At equivalent doses, saNppa achieved greater efficacy than conventional mRNA. Single-nucleus transcriptomics identified natriuretic peptide receptor 1–positive ( Npr1 + ) endothelial and epicardial cells as primary effectors, with saNppa-LNPs reshaping their paracrine profile to promote cardiomyocyte regeneration and suppress fibrosis. Longitudinal biosafety assessments revealed no systemic toxicity. Together, these results demonstrate that one-shot saNppa-LNP therapy offers durable cardioprotection, supporting the broader potential of saRNA-LNP–based approaches for cardiac therapy.
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , edau9394
Top Cited PapersOpen AccessSingle intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Self-amplifying RNA (saRNA) enables sustained protein expression from a single administration. In this study, we developed an intramuscular saRNA-lipid nanoparticle (saNppa-LNP) therapy encoding natriuretic peptide type A ( Nppa ) for cardioprotection. A single injection induced sustained pro–atrial natriuretic peptide (pro-ANP) secretion for 4 weeks; pro-ANP was subsequently cleaved by the cardiac protease corin into active ANP, producing robust cardioprotection in mouse and swine myocardial infarction models. At equivalent doses, saNppa achieved greater efficacy than conventional mRNA. Single-nucleus transcriptomics identified natriuretic peptide receptor 1–positive ( Npr1 + ) endothelial and epicardial cells as primary effectors, with saNppa-LNPs reshaping their paracrine profile to promote cardiomyocyte regeneration and suppress fibrosis. Longitudinal biosafety assessments revealed no systemic toxicity. Together, these results demonstrate that one-shot saNppa-LNP therapy offers durable cardioprotection, supporting the broader potential of saRNA-LNP–based approaches for cardiac therapy.
- Open Access
- 18 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Plant-derived hydrogel and photosynthetic nano-units for myocardial infarction therapy
Ischemic injury and reperfusion injury collectively determine the total infarct size, a major prognostic factor following myocardial infarction (MI). Therefore, addressing both ischemic and reperfusion stages could substantially reduce infarct size and improve clinical outcomes. In this study, we develop a two-component therapeutic system from different parts of Glycyrrhiza: a functional hydrogel made from glycyrrhizic acid extracted from the stem and root, and nanosized chloroplast units (NCUs) derived from leaves. The hydrogel demonstrates therapeutic effects during both hypoxia and reoxygenation stages in vitro, while the photosynthetic NCUs alleviate hypoxia injury by providing ATP and NADPH under illumination. Subsequent in vivo study reveals the most significant therapeutic effect in the combination group (NCU plus hydrogel), which effectively treats both ischemic and reperfusion stages. Our study highlights the cross-species application of plant photosynthetic mechanisms in MI treatment and confirms that simultaneous treatment of ischemia and reperfusion is more effective than treating either stage alone, offering a promising therapeutic strategy for MI.
- 18 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessPlant-derived hydrogel and photosynthetic nano-units for myocardial infarction therapy
Ischemic injury and reperfusion injury collectively determine the total infarct size, a major prognostic factor following myocardial infarction (MI). Therefore, addressing both ischemic and reperfusion stages could substantially reduce infarct size and improve clinical outcomes. In this study, we develop a two-component therapeutic system from different parts of Glycyrrhiza: a functional hydrogel made from glycyrrhizic acid extracted from the stem and root, and nanosized chloroplast units (NCUs) derived from leaves. The hydrogel demonstrates therapeutic effects during both hypoxia and reoxygenation stages in vitro, while the photosynthetic NCUs alleviate hypoxia injury by providing ATP and NADPH under illumination. Subsequent in vivo study reveals the most significant therapeutic effect in the combination group (NCU plus hydrogel), which effectively treats both ischemic and reperfusion stages. Our study highlights the cross-species application of plant photosynthetic mechanisms in MI treatment and confirms that simultaneous treatment of ischemia and reperfusion is more effective than treating either stage alone, offering a promising therapeutic strategy for MI.
- Top Cited Papers
- 11 January 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (4) , 565-575
Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity
Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential as robust tumour suppressors. However, their applications are limited due to off-target toxicity. Here we report on a strategy involving the inhalation of IL-12 messenger RNA, encapsulated within extracellular vesicles. Inhalation and preferential uptake by cancer cells results in targeted delivery and fewer systemic side effects. The IL-12 messenger RNA generates interferon-γ production in both innate and adaptive immune-cell populations. This activation consequently incites an intense activation state in the tumour microenvironment and augments its immunogenicity. The increased immune response results in the expansion of tumour cytotoxic immune effector cells, the formation of immune memory, improved antigen presentation and tumour-specific T cell priming. The strategy is demonstrated against primary neoplastic lesions and provides profound protection against subsequent tumour rechallenge. This shows the potential for locally delivered cytokine-based immunotherapies to address orthotopic and metastatic lung tumours.
- 11 January 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (4) , 565-575
Top Cited PapersInhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity
Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential as robust tumour suppressors. However, their applications are limited due to off-target toxicity. Here we report on a strategy involving the inhalation of IL-12 messenger RNA, encapsulated within extracellular vesicles. Inhalation and preferential uptake by cancer cells results in targeted delivery and fewer systemic side effects. The IL-12 messenger RNA generates interferon-γ production in both innate and adaptive immune-cell populations. This activation consequently incites an intense activation state in the tumour microenvironment and augments its immunogenicity. The increased immune response results in the expansion of tumour cytotoxic immune effector cells, the formation of immune memory, improved antigen presentation and tumour-specific T cell priming. The strategy is demonstrated against primary neoplastic lesions and provides profound protection against subsequent tumour rechallenge. This shows the potential for locally delivered cytokine-based immunotherapies to address orthotopic and metastatic lung tumours.
- Top Cited Papers
- 26 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (11) , 18253-18265
Penetrating Macrophage-Based Nanoformulation for Periodontitis Treatment
Periodontitis is a chronic inflammatory disease caused by the interaction of oral microorganisms with the host immune response. Porphyromonas gingivalis (P.g.) acts as a key mediator in subverting the homeostasis of the local immune system. On the one hand, P.g. inhibits phagocytosis and the killing capacity of immune cells. On the other hand, P.g. increases selective cytokine release, which is beneficial to its further proliferation. Here, we prepared a penetrating macrophage-based nanoformulation (MZ@PNM)-encapsulating hydrogel (MZ@PNM@GCP) that responded to the periodontitis microenvironment. MZ@PNM targeted P.g. via the Toll-like receptor complex 2/1 (TLR2/1) on its macrophage-mimicking membrane, then directly killed P.g. through disruption of bacterial structural integrity by the cationic nanoparticles and intracellular release of an antibacterial drug, metronidazole (MZ). Meanwhile, MZ@PNM interrupted the specific binding of P.g. to immune cells and neutralized complement component 5a (C5a), preventing P.g. subversion of periodontal host immune response. Overall, MZ@PNM@GCP showed potent efficacy in periodontitis treatment, restoring local immune function and killing pathogenic bacteria, while exhibiting favorable biocompatibility, all of which have been demonstrated both in vivo and in vitro.
- 26 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (11) , 18253-18265
Top Cited PapersPenetrating Macrophage-Based Nanoformulation for Periodontitis Treatment
Periodontitis is a chronic inflammatory disease caused by the interaction of oral microorganisms with the host immune response. Porphyromonas gingivalis (P.g.) acts as a key mediator in subverting the homeostasis of the local immune system. On the one hand, P.g. inhibits phagocytosis and the killing capacity of immune cells. On the other hand, P.g. increases selective cytokine release, which is beneficial to its further proliferation. Here, we prepared a penetrating macrophage-based nanoformulation (MZ@PNM)-encapsulating hydrogel (MZ@PNM@GCP) that responded to the periodontitis microenvironment. MZ@PNM targeted P.g. via the Toll-like receptor complex 2/1 (TLR2/1) on its macrophage-mimicking membrane, then directly killed P.g. through disruption of bacterial structural integrity by the cationic nanoparticles and intracellular release of an antibacterial drug, metronidazole (MZ). Meanwhile, MZ@PNM interrupted the specific binding of P.g. to immune cells and neutralized complement component 5a (C5a), preventing P.g. subversion of periodontal host immune response. Overall, MZ@PNM@GCP showed potent efficacy in periodontitis treatment, restoring local immune function and killing pathogenic bacteria, while exhibiting favorable biocompatibility, all of which have been demonstrated both in vivo and in vitro.
- 28 September 2022
- Published by S. Karger AG in Cells Tissues Organs
- Vol. 213 (1) , 40-54
Hepatocyte Growth Factor Promotes Differentiation Potential and Stress Response of Human Stem Cells from Apical Papilla
Harsh local microenvironment, such as hypoxia and lack of instructive clues for transplanted stem cells, presents the serious obstacle for stem cell therapies’ efficacy. Therefore, continued efforts have been taken to improve stem cells’ viability and plasticity. Hepatocyte growth factor (HGF) has previously been reported to mitigate the complications of various human diseases in animal model studies and in some clinical trials. Besides, human stem cells from the root apical papilla (SCAP) are deemed a better resource of mesenchymal stem cells due to derived stem cells holding greater amplification ability in vitro compared with those from other dental resources. To move forward, evaluating effects and understanding underlying molecular mechanisms of HGF on SCAP for periodontal regeneration are needed. In this study, HGF was transgenically expressed in SCAP, and it was found that HGF enhanced osteo/dentinogenic differentiation capacity of SCAP compared with those of non-treated control in an ectopic mineralization model. Moreover, HGF reduced the apoptosis of SCAP under both normoxic and hypoxic conditions, whereas the combination of HGF and hypoxia exposure had inhibitory effects on cell proliferation during an 8-day in vitro culture period. Transcriptome analysis further revealed that suppressed cell cycle progression and activated BMP/TGFβ, Hedgehog, WNT, FGF, HOX, and other morphogen family members result upon HGF overexpression, which may render SCAP recapitulate part of neural crest stem cell characteristics. Moreover, strengthened stress response modulation such as unfolded protein response, macroautophagy, and anti-apoptotic molecules might explain the increased viability of SCAP. In all, our results imply that these potential mechanisms underlying HGF-promoting SCAP differentiation could be further elucidated and harnessed to improve periodontal tissue regeneration.
- 28 September 2022
- Published by S. Karger AG in Cells Tissues Organs
- Vol. 213 (1) , 40-54
Hepatocyte Growth Factor Promotes Differentiation Potential and Stress Response of Human Stem Cells from Apical Papilla
Harsh local microenvironment, such as hypoxia and lack of instructive clues for transplanted stem cells, presents the serious obstacle for stem cell therapies’ efficacy. Therefore, continued efforts have been taken to improve stem cells’ viability and plasticity. Hepatocyte growth factor (HGF) has previously been reported to mitigate the complications of various human diseases in animal model studies and in some clinical trials. Besides, human stem cells from the root apical papilla (SCAP) are deemed a better resource of mesenchymal stem cells due to derived stem cells holding greater amplification ability in vitro compared with those from other dental resources. To move forward, evaluating effects and understanding underlying molecular mechanisms of HGF on SCAP for periodontal regeneration are needed. In this study, HGF was transgenically expressed in SCAP, and it was found that HGF enhanced osteo/dentinogenic differentiation capacity of SCAP compared with those of non-treated control in an ectopic mineralization model. Moreover, HGF reduced the apoptosis of SCAP under both normoxic and hypoxic conditions, whereas the combination of HGF and hypoxia exposure had inhibitory effects on cell proliferation during an 8-day in vitro culture period. Transcriptome analysis further revealed that suppressed cell cycle progression and activated BMP/TGFβ, Hedgehog, WNT, FGF, HOX, and other morphogen family members result upon HGF overexpression, which may render SCAP recapitulate part of neural crest stem cell characteristics. Moreover, strengthened stress response modulation such as unfolded protein response, macroautophagy, and anti-apoptotic molecules might explain the increased viability of SCAP. In all, our results imply that these potential mechanisms underlying HGF-promoting SCAP differentiation could be further elucidated and harnessed to improve periodontal tissue regeneration.
- 26 May 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 447, 116088
Comparison of the pharmacokinetics of Crocin-I in normoxic and hypoxic rats
- 26 May 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 447, 116088
Comparison of the pharmacokinetics of Crocin-I in normoxic and hypoxic rats
- 5 February 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 172, 89-100
Discovery in polyethylene glycol immunogenicity: The characteristic of intergenerational inheritance of anti-polyethylene glycol IgG
- 5 February 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 172, 89-100
Discovery in polyethylene glycol immunogenicity: The characteristic of intergenerational inheritance of anti-polyethylene glycol IgG